Bausch + Lomb Corp(BLCO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.48 | Insider Own | 88.79% | Shs Outstand | 357.1M | Perf Week | -2.5% |
| Market Cap | 6.27B | Forward P/E | 15.95 | EPS next Y | 38.51% | Insider Trans | -0.01% | Shs Float | 40.0M | Perf Month | 4.03% |
| Enterprise Value | 11.07B | PEG | 0.38 | EPS next Q | 0.21 | Inst Own | 10.01% | Short Float | 7.94% | Perf Quarter | 15.01% |
| Income | -0.17B | P/S | 1.18 | EPS this Y | 55.72% | Inst Trans | -0.53% | Short Ratio | 7.87 | Perf Half Y | 0.29% |
| Sales | 5.32B | P/B | 0.98 | EPS next 5Y | 41.87% | ROA | -1.24% | Short Interest | 3.18M | Perf YTD | 2.75% |
| Book/sh | 17.86 | P/C | 16.58 | EPS past 3/5Y | - | ROE | -2.67% | 52W High | -7.22% ($18.92) | Perf Year | 17% |
| Cash/sh | 1.06 | P/FCF | 44.73 | Sales past 3/5Y | 10.62% 8.38% | ROIC | -1.49% | 52W Low | 27.5% ($13.77) | Perf 3Y | 1.8% |
| Dividend Est. | - | EV/EBITDA | 13.57 | EPS Y/Y TTM | 37.7% | Gross Margin | 56.97% | Volatility(W/M) | 2.79% 2.46% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 2.08 | Sales Y/Y TTM | 8.85% | Oper. Margin | 7.61% | ATR (14) | 0.47 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.02 | EPS Q/Q | 77.64% | Profit Margin | -3.21% | RSI (14) | 55.31 | Recom | 2.27 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.55 | Sales Q/Q | 9.08% | SMA20 | 0.67% ($17.43) | Beta | 0.55 | Target Price | $19.08 |
| Payout | - | Debt/Eq | 0.8 | Earnings | 2026/7/29 | SMA50 | 3.9% ($16.89) | Rel Volume | 1.29 | Prev Close | $17.79 |
| Employees | 13000 | LT Debt/Eq | 0.8 | EPS/Sales Surpr. | -2.85% 1.81% | SMA200 | 5.75% ($16.6) | Avg Volume(3M) | 0.40M | Price | $17.55 |
| IPO | 2022/5/6 | Option/Short | Yes/Yes | Trades | 4842 | Volume | 520,535 | Change | -1.35% |
Company
BLCO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
👁️ This U.S. ophthalmic healthcare company offers a broad range of eye health products. It supplies contact lenses and lens care solutions, ophthalmic pharmaceuticals, and cataract and other ophthalmic surgical equipment and consumables, making it a medical device stock whose performance is tied to aging-driven eye care demand and new product cycles. A key feature is its high share of recurring revenue from lenses and consumables.
Over the past 1 year, roughly in the middle
7% below its 1-year high.
BLCO has weak earning power
7.61% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +55.7% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Long-term returns are close to the market
Would have changed by +1.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 10.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
MGMT 0.01%
MYHB 0.01%
XHYH 0.01%
BSJS 0.01%
IBHH 0.01%It ranks #4 in the industry
Based on market cap of $6B.
BLCO $6B PER -
ISRG $127B PER 41.3
BDX $48B PER 53.2
MDLN $43B PER 38.0
FAQ
What kind of company is BLCO?
BLCO belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of BLCO?
The market cap of BLCO is approximately $6.3B, ranking 1,221 within its sector.
What is the 52-week high and low for BLCO?
BLCO has recorded a 52-week high of $18.92 and a low of $13.77.
